

JOURNAL OF CLINICAL ONCOLOGY

Official Journal of the American Society of Clinical Oncology

Vol 26, No 14

C O N T E N T S

May 10, 2008

Celebrating 25 Years of JCO

FROM JCO 1983

Intensive Melphalan Chemotherapy and Cryopreserved Autologous Bone Marrow Transplantation for the Treatment of Refractory Cancer

Hillard M. Lazarus, Roger H. Herzig, John Graham-Pole, Steven N. Wolff, Gordon L. Phillips, Sarah Strandjord, David Hurd, Walter Forman, Erlinda M. Gordon, Peter Coccia, Samuel Gross, and Geoffrey P. Herzig c118

COMMENTARY

High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later

Hillard M. Lazarus, Gordon L. Phillips, Roger H. Herzig, David D. Hurd, Steven N. Wolff, and Geoffrey P. Herzig 2240

Editorials

Comprehensive Single Nucleotide Polymorphism Study Supports the Role of MDM2 in p53-Competent Chronic Lymphocytic Leukemia

David M. Lucas and John C. Byrd (see article on page 2252) 2244

Primary Care Physicians and Oncologists Are Players on the Same Team

Eva Grunfeld (see article on page 2272) 2246

Radical Prostatectomy by Open or Laparoscopic/Robotic Techniques: An Issue of Surgical Device or Surgical Expertise?

Michael L. Blute (see article on page 2278) 2248

Combining a Peptide Vaccine With High-Dose Interleukin-2

Paul B. Chapman (see article on page 2292) 2250

Original Reports

HEMATOLOGIC MALIGNANCIES

① MDM2 SNP309 Is Associated With Poor Outcome in B-Cell Chronic Lymphocytic Leukemia

Irina Gryshchenko, Sebastian Hofbauer, Markus Stoecher, Peter T. Daniel, Michael Steurer, Alexander Gaiger, Karin Eigenberger, Richard Greil, and Inge Tinhofer (see editorial on page 2244) 2252

(continued on following page)

Journal of Clinical Oncology (ISSN 0732-183X) is published 36 times a year, three times monthly, by American Society of Clinical Oncology, 1900 Duke St, Suite 200, Alexandria, VA 22314. Periodicals postage is paid at Alexandria, VA, and at additional mailing offices. Publication Mail Agreement Number 863289.

Editorial correspondence should be addressed to Daniel G. Haller, MD, *Journal of Clinical Oncology*, 330 John Carlyle St, Suite 300, Alexandria, VA 22314. Telephone: (703) 797-1900; Fax: (703) 684-8720. E-mail: jco@asco.org. Internet: www.jco.org.

POSTMASTER: ASCO members send change of address to American Society of Clinical Oncology, 1900 Duke St, Suite 200, Alexandria, VA 22314. Nonmembers send change of address to *Journal of Clinical Oncology* Customer Service, 330 John Carlyle St, Suite 300, Alexandria, VA 22314.

2008 annual subscription rates, effective January 1, 2008: United States and possessions: individual, \$535; single issue, \$40. International: individual, \$735; single issue, \$50. Institutions: Tier 1: \$735 US, \$1,015 Int'l; Tier 2: \$855 US, \$1,135 Int'l; Tier 3: \$1,235 US, \$1,505 Int'l; Tier 4: \$1,360 US, \$1,630 Int'l; Tier 5: contact JCO for a quote. See <http://www.jco.org/subscriptions/tieredpricing.shtml> for descriptions of each tier. Student and resident: United States and possessions: \$265; all other countries, \$365. To receive student/resident rate, orders must be accompanied by name of affiliated institution, date of term, and the signature of program/residency coordinator on institution letterhead. Orders will be billed at individual rate until proof of status is received. Current prices are in effect for back volumes and back issues. Back issues sold in conjunction with a subscription rate are on a prorated basis. Subscriptions are accepted on a 12-month basis. Prices are subject to change without notice. Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability. JCO Legacy Archive (electronic back issues from January 1983 through December 1998) is also available; please inquire.

Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014

Daniel O. Persky, Joseph M. Unger, Catherine M. Spier, Baldassarre Stea, Michael LeBlanc, Matthew J. McCarty, Lisa M. Rimsza, Richard I. Fisher, and Thomas P. Miller 2258

Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire

Steven Le Gouill, Noel Milpied, Agnès Buzyn, Régis Peffault De Latour, Jean-Paul Vernant, Mohamad Mohty, Marie-Pierre Moles, Krime Bouabdallah, Claude-Eric Bulabois, Jehan Dupuis, Bernard Rio, Nicole Gratecos, Ibrahim Yakoub-Agha, Michel Attal, Olivier Tournilhac, Didier Decaudin, Jean-Henry Bourhis, Didier Blaise, Christelle Volteau, and Mauricette Michallet 2264

SUPPORTIVE CARE AND QUALITY OF LIFE

Tailored Chemotherapy Information Faxed to General Practitioners Improves Confidence in Managing Adverse Effects and Satisfaction With Shared Care: Results From a Randomized Controlled Trial

Michael Jefford, Carl Baravelli, Paul Dudgeon, Adrian Dabscheck, Melanie Evans, Michael Moloney, and Penelope Schofield (see editorial on page 2246) 2272

GENITOURINARY CANCER

Utilization and Outcomes of Minimally Invasive Radical Prostatectomy

Jim C. Hu, Qin Wang, Chris L. Pashos, Stuart R. Lipsitz, and Nancy L. Keating (see editorial on page 2248) 2278

Lapatinib Versus Hormone Therapy in Patients With Advanced Renal Cell Carcinoma: A Randomized Phase III Clinical Trial

Alain Ravaud, Robert Hawkins, Jason P. Gardner, Hans von der Maase, Niko Zantl, Peter Harper, Frédéric Rolland, Bruno Audhuy, Jean-Pascal Machiels, Frank Pétavy, Martin Gore, Patrick Schöffski, and Iman El-Hariry 2285

MELANOMA

Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced Melanoma

Jeffrey A. Sosman, Carole Carrillo, Walter J. Urba, Lawrence Flaherty, Michael B. Atkins, Joseph I. Clark, Janet Dutcher, Kim A. Margolin, James Mier, Jarod Gollob, John M. Kirkwood, David J. Panka, Nancy A. Crosby, Kevin O’Boyle, Bonnie LaFleur, and Marc S. Ernstoff (see editorial on page 2250) 2292

Phase II Study of Extended-Dose Temozolomide in Patients With Melanoma

Petra Rietschel, Jedd D. Wolchok, Susan Krown, Scott Gerst, Achim A. Jungbluth, Klaus Busam, Katherine Smith, Irene Orlow, Katherine Panageas, and Paul B. Chapman 2299

AIDS-RELATED CANCER

Use of Antidepressants and Risk of Cancer in Individuals Infected With HIV

Justin Stebbing, Tom Powles, Sundhiya Mandalia, Mark Nelson, Brian Gazzard, and Mark Bower 2305

GASTROINTESTINAL CANCER

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

Alberto F. Sobrero, Joan Maurel, Louis Fehrenbacher, Werner Scheithauer, Yousif A. Abubakr, Manfred P. Lutz, M. Eugenia Vega-Villegas, Cathy Eng, Ernst U. Steinhauer, Jana Prausova, Heinz-Josef Lenz, Christophe Borg, Gary Middleton, Hendrik Kröning, Gabriele Luppi, Oliver Kisker, Angela Zobel, Christiane Langer, Justin Kopit, and Howard A. Burris III 2311

Bortezomib With or Without Irinotecan in Relapsed or Refractory Colorectal Cancer: Results From a Randomized Phase II Study

Peter S. Kozuch, Caio Max Rocha-Lima, Tomislav Dragovich, Howard Hochster, Bert H. O’Neil, Omar T. Atiq, J. Marc Pipas, David P. Ryan, and Heinz-Josef Lenz 2320

Quantitative Analysis of Methylation of Genomic Loci in Early-Stage Rectal Cancer Predicts Distant Recurrence

Michiel F.G. de Maat, Cornelis J.H. van de Velde, Martijn P.J. van der Werff, Hein Putter, Naoyuki Umetani, Elma Meershoek Klein-Kranenbarg, Roderick R. Turner, J. Han J.M. van Krieken, Anton Bilchik, Rob A.E.M. Tollenaar, and Dave S.B. Hoon 2327

① **Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set**

Michael J. O'Connell, Megan E. Campbell, Richard M. Goldberg, Axel Grothey, Jean-François Seitz, Jacqueline K. Benedetti, Thierry André, Daniel G. Haller, and Daniel J. Sargent 2336

THORACIC ONCOLOGY

① **Safety and Efficacy of Darbepoetin Alfa in Previously Untreated Extensive-Stage Small-Cell Lung Cancer Treated With Platinum Plus Etoposide**

Robert Pirker, Rodryg A. Ramlau, Wolfgang Schuette, Petr Zatloukal, Irene Ferreira, Tom Lillie, and Johan F. Vansteenkiste 2342

Erlotinib for Advanced Non–Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

Paul Wheatley-Price, Keyue Ding, Lesley Seymour, Gary M. Clark, and Frances A. Shepherd 2350

BREAST CANCER

Decision Making Regarding Prophylactic Mastectomy: Stability of Preferences and the Impact of Anticipated Feelings of Regret

Sandra van Dijk, Mariëlle S. van Roosmalen, Wilma Otten, and Peep F.M. Stalmeier 2358

① **Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 From the Cancer and Leukemia Group B**

Michael P. DiGiovanna, David F. Stern, Susan Edgerton, Gloria Broadwater, Lynn G. Dressler, Daniel R. Budman, I. Craig Henderson, Larry Norton, Edison T. Liu, Hyman B. Muss, Donald A. Berry, Daniel F. Hayes, and Ann D. Thor 2364

① **Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy**

Paul L. Nguyen, Alphonse G. Taghian, Matthew S. Katz, Andrzej Niemierko, Rita F. Abi Raad, Whitney L. Boon, Jennifer R. Bellon, Julia S. Wong, Barbara L. Smith, and Jay R. Harris 2373

PEDIATRIC ONCOLOGY

Redefining the Role of Doxorubicin for the Treatment of Children With Hepatoblastoma

Marcio H. Malogolowkin, Howard M. Katzenstein, Mark Krailo, Zhengjia Chen, John J. Quinn, Marleta Reynolds, and Jorge A. Ortega 2379

Prognostic Factors in Metastatic Rhabdomyosarcomas: Results of a Pooled Analysis From United States and European Cooperative Groups

Odile Oberlin, Annie Rey, Elizabeth Lyden, Gianni Bisogno, Michael C.G. Stevens, William H. Meyer, Modesto Carli, and James R. Anderson 2384

① **Safety and Efficacy of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Pediatric Acute Myeloid Leukemia: A Report From The Children's Oncology Group**

Richard Aplenc, Todd A. Alonzo, Robert B. Gerbing, Beverly J. Lange, Craig A. Hurwitz, Robert J. Wells, Irwin Bernstein, Patrick Buckley, Kathleen Krimmel, Franklin O. Smith, Eric L. Sievers, and Robert J. Arceci 2390

Review Article

Interventions for Alleviating Cancer-Related Dyspnea: A Systematic Review

Irit Ben-Aharon, Anat Gafter-Gvili, Mical Paul, Leonard Leibovici, and Salomon M. Stemmer 2396

Diagnosis in Oncology

Bowel Perforation After Radiotherapy in a Patient Receiving Sorafenib

Natascha A.J.B. Peters, Dick J. Richel, Joost J.C. Verhoeff, and Lukas J.A. Stalpers 2405

Cetuximab-Related Tumor Lysis Syndrome in Metastatic Colon Carcinoma

Ganapathy Krishnan, Karl D'Silva, and Anas Al-Janadi 2406

Phenotypic Evolution of Waldenstrom's Macroglobulinemia to Extramedullary Plasmacytoma

Qaiser Bashir, Choon-Kee Lee, Rodney W. Stuart, Maxwell L. Smith, John Ryder, and Ricardo Gonzalez 2408

Correspondence

Hillmen Trial of Alemtuzumab in First-Line Chronic Lymphocytic Leukemia Still Provides Valuable Information

Cynthia Sirard and Elizabeth G. Trehu 2411

In Reply

Joseph M. Flynn and John C. Byrd 2412

Is Chemotherapy the Standard for Asymptomatic Androgen-Independent Prostate Cancer?

Chadi Nabhan 2413

In Reply

Dominik Berthold and Ian Tannock 2414

Are Urokinase Rinses Needed to Reduce Catheter-Related Bloodstream Infections When Standard Preventive Guidelines Are Observed?

François Blot, Bertrand Gachot, and Gérard Nitenberg 2415

In Reply

Cornelis J. van Rooden, Emile F. Schippers, and Menno V. Huisman 2416

Selection of a Taxane As Well As Anthracycline for Early Breast Cancer

Peter H. Graham 2416

In Reply

Michele De Laurentiis and Sabino De Placido 2417

Chemoprevention of Head and Neck Cancers: Promising New Biochemical Prospects

Shailendra Kapoor 2417

In Reply

Fadlo R. Khuri and Dong M. Shin 2418

CHEK2*1100delC Screening of Asian Women With a Family History of Breast Cancer

Is Unwarranted

Ann S.G. Lee and Peter Ang 2419

In Reply

Maren Weischer, Stig E. Bojesen, and Børge G. Nordestgaard 2419

e. Karyotype Evolution on Fluorescent In Situ Hybridization Analysis Is Associated With Short Survival in Patients With Chronic Lymphocytic Leukemia and Is Related to CD49d Expression

Tait D. Shanafelt, Curtis Hanson, Gordon W. Dewald, Thomas E. Witzig, Betsy LaPlant, Jennifer Abrahamzon, Diane F. Jelinek, and Neil E. Kay e5

Erratum 2421

Also in This Issue

Information for Subscribers

Announcements

Information for Contributors

Manuscript Submission Checklist

Current Abstracts

Calendar of Oncology Events



Online supplementary information available at www.jco.org



Article was published online ahead of print at www.jco.org



Additional correspondence available online at www.jco.org